Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Radiotherapy | Research

PErspective and current status of Radiotherapy Service in IRan (PERSIR)-1 study: assessment of current external beam radiotherapy facilities, staff and techniques compared to the international guidelines

Authors: Arefeh Saeedian, Fatemeh-sadat Tabatabaei, Amirali Azimi, Mohammad Babaei, Marzieh Lashkari, Ebrahim Esmati, Zeinab Abiar, Leila Moadabshoar, Saleh Sandoughdaran, Mitchell Kamrava, Arya Amini, Reza Ghalehtaki

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background and purpose

Radiotherapy (RT) is an essential treatment modality against cancer and becoming even more in demand due to the anticipated increase in cancer incidence. Due to the rapid development of RT technologies amid financial challenges, we aimed to assess the available RT facilities and the issues with achieving health equity based on current equipment compared to the previous reports from Iran.

Materials and methods

A survey arranged by the Iran Cancer Institute's Radiation Oncology Research Center (RORC) was sent to all of the country's radiotherapy centers in 2022. Four components were retrieved: the reimbursement type, equipment, human resources, and patient load. To calculate the radiotherapy utilization rate (RUR), the Lancet Commission was used. The findings were compared with the previous national data.

Results

Seventy-six active radiotherapy centers with 123 Linear accelerators (LINACs) were identified. The centers have been directed in three ways. 10 (20 LINACs), 36 (50 LINACs), and 30 centers (53 LINACs) were charity-, private-, and public-based, respectively. Four provinces had no centers. There was no active intraoperative radiotherapy machine despite its availability in 4 centers. One orthovoltage X-ray machine was active and 14 brachytherapy devices were treating patients. There were 344, 252, and 419 active radiation oncologists, medical physicists, and radiation therapy technologists, respectively. The ratio of LINAC and radiation oncologists to one million populations was 1.68 and 4.10, respectively. Since 2017, 35±5 radiation oncology residents have been trained each year.

Conclusion

There has been a notable growth in RT facilities since the previous reports and Iran's situation is currently acceptable among LMICs. However, there is an urgent need to improve the distribution of the RT infrastructure and provide more facilities that can deliver advanced techniques.
Literature
2.
go back to reference Stewart BW, Kleihues P. World cancer report. Lyon: IARC press; 2003. Stewart BW, Kleihues P. World cancer report. Lyon: IARC press; 2003.
3.
go back to reference Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556–63.CrossRefPubMed Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556–63.CrossRefPubMed
4.
go back to reference Roshandel G, Ferlay J, Ghanbari-Motlagh A, Partovipour E, Salavati F, Aryan K, et al. Cancer in Iran 2008 to 2025: Recent incidence trends and short-term predictions of the future burden. Int J Cancer. 2021;149(3):594–605.CrossRefPubMed Roshandel G, Ferlay J, Ghanbari-Motlagh A, Partovipour E, Salavati F, Aryan K, et al. Cancer in Iran 2008 to 2025: Recent incidence trends and short-term predictions of the future burden. Int J Cancer. 2021;149(3):594–605.CrossRefPubMed
5.
go back to reference Aloosh M, Salavati A, Aloosh A. Economic sanctions threaten population health: the case of Iran. Public health. 2019;169:10–3.CrossRefPubMed Aloosh M, Salavati A, Aloosh A. Economic sanctions threaten population health: the case of Iran. Public health. 2019;169:10–3.CrossRefPubMed
6.
go back to reference Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B, et al. Expanding global access to radiotherapy. The lancet oncology. 2015;16(10):1153–86.CrossRefPubMed Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B, et al. Expanding global access to radiotherapy. The lancet oncology. 2015;16(10):1153–86.CrossRefPubMed
7.
go back to reference Einck JP, Hudson A, Shulman AC, Yashar CM, Dieng MM, Diagne M, et al. Implementation of a high-dose-rate brachytherapy program for carcinoma of the cervix in Senegal: a pragmatic model for the developing world. Int J Radiat Oncol Biol Phys. 2014;89(3):462–7.CrossRefPubMed Einck JP, Hudson A, Shulman AC, Yashar CM, Dieng MM, Diagne M, et al. Implementation of a high-dose-rate brachytherapy program for carcinoma of the cervix in Senegal: a pragmatic model for the developing world. Int J Radiat Oncol Biol Phys. 2014;89(3):462–7.CrossRefPubMed
8.
go back to reference Ameri A, Barzegartahamtan M, Ghavamnasiri M, Mohammadpour R, Dehghan H, Sebzari A, et al. Current and future challenges of radiation oncology in Iran: a report from the Iranian society of clinical oncology. Clin Oncol. 2018;30(4):262–8.CrossRef Ameri A, Barzegartahamtan M, Ghavamnasiri M, Mohammadpour R, Dehghan H, Sebzari A, et al. Current and future challenges of radiation oncology in Iran: a report from the Iranian society of clinical oncology. Clin Oncol. 2018;30(4):262–8.CrossRef
10.
go back to reference Davari M, Haycox A, Walley T. The Iranian health insurance system; past experiences, present challenges and future strategies. Iran J Public Health. 2012;41(9):1.PubMedPubMedCentral Davari M, Haycox A, Walley T. The Iranian health insurance system; past experiences, present challenges and future strategies. Iran J Public Health. 2012;41(9):1.PubMedPubMedCentral
11.
go back to reference Maroongroge S, Wallington DG, Taylor PA, Zhu D, Guadagnolo BA, Smith BD, et al. Geographic access to radiation therapy facilities in the United States. Int J Radiat Oncol Biol Phys. 2022;112(3):600–10.CrossRefPubMed Maroongroge S, Wallington DG, Taylor PA, Zhu D, Guadagnolo BA, Smith BD, et al. Geographic access to radiation therapy facilities in the United States. Int J Radiat Oncol Biol Phys. 2022;112(3):600–10.CrossRefPubMed
12.
go back to reference Datta NR, Samiei M, Bodis S. Radiation therapy infrastructure and human resources in low-and middle-income countries: present status and projections for 2020. Int J Radiat Oncol Biol Phys. 2014;89(3):448–57.CrossRefPubMed Datta NR, Samiei M, Bodis S. Radiation therapy infrastructure and human resources in low-and middle-income countries: present status and projections for 2020. Int J Radiat Oncol Biol Phys. 2014;89(3):448–57.CrossRefPubMed
13.
go back to reference Barton MB, Jacob S, Shafiq J, Wong K, Thompson SR, Hanna TP, Delaney GP. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol. 2014;112(1):140–4.CrossRefPubMed Barton MB, Jacob S, Shafiq J, Wong K, Thompson SR, Hanna TP, Delaney GP. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol. 2014;112(1):140–4.CrossRefPubMed
14.
go back to reference Dunscombe P, Grau C, Defourny N, Malicki J, Borras JM, Coffey M, et al. Guidelines for equipment and staffing of radiotherapy facilities in the European countries: final results of the ESTRO-HERO survey. Radiother Oncol. 2014;112(2):165–77.CrossRefPubMed Dunscombe P, Grau C, Defourny N, Malicki J, Borras JM, Coffey M, et al. Guidelines for equipment and staffing of radiotherapy facilities in the European countries: final results of the ESTRO-HERO survey. Radiother Oncol. 2014;112(2):165–77.CrossRefPubMed
15.
go back to reference Lievens Y, Defourny N, Coffey M, Borras JM, Dunscombe P, Slotman B, et al. Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014;112(2):178–86.CrossRefPubMed Lievens Y, Defourny N, Coffey M, Borras JM, Dunscombe P, Slotman B, et al. Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. 2014;112(2):178–86.CrossRefPubMed
16.
go back to reference Barton M, Hudson H, Delaney G, Gruver P, Liu Z. Patterns of retreatment by radiotherapy. Clin Oncol. 2011;23(1):10–8.CrossRef Barton M, Hudson H, Delaney G, Gruver P, Liu Z. Patterns of retreatment by radiotherapy. Clin Oncol. 2011;23(1):10–8.CrossRef
17.
go back to reference Bentzen SM, Heeren G, Cottier B, Slotman B, Glimelius B, Lievens Y, Van den Bogaert W. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol. 2005;75(3):355–65.CrossRefPubMed Bentzen SM, Heeren G, Cottier B, Slotman B, Glimelius B, Lievens Y, Van den Bogaert W. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol. 2005;75(3):355–65.CrossRefPubMed
18.
go back to reference Slotman BJ, Cottier B, Bentzen SM, Heeren G, Lievens Y, Van den Bogaert W. Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1. Radiother Oncol. 2005;75(75):75 E1-E6. Slotman BJ, Cottier B, Bentzen SM, Heeren G, Lievens Y, Van den Bogaert W. Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1. Radiother Oncol. 2005;75(75):75 E1-E6.
19.
go back to reference Zubizarreta E, Fidarova E, Healy B, Rosenblatt E. Need for radiotherapy in low and middle income countries–the silent crisis continues. Clin Oncol. 2015;27(2):107–14.CrossRef Zubizarreta E, Fidarova E, Healy B, Rosenblatt E. Need for radiotherapy in low and middle income countries–the silent crisis continues. Clin Oncol. 2015;27(2):107–14.CrossRef
20.
go back to reference Doshmangir L, Bazyar M, Rashidian A, Gordeev VS. Iran health insurance system in transition: equity concerns and steps to achieve universal health coverage. Int J Equity Health. 2021;20(1):1–14.CrossRef Doshmangir L, Bazyar M, Rashidian A, Gordeev VS. Iran health insurance system in transition: equity concerns and steps to achieve universal health coverage. Int J Equity Health. 2021;20(1):1–14.CrossRef
21.
go back to reference Motlagh SN, Gorji HA, Mahdavi G, Ghaderi H. Main determinants of supplementary health insurance demand:(Case of Iran). Glob J Health Sci. 2015;7(6):285.PubMedCentral Motlagh SN, Gorji HA, Mahdavi G, Ghaderi H. Main determinants of supplementary health insurance demand:(Case of Iran). Glob J Health Sci. 2015;7(6):285.PubMedCentral
22.
go back to reference Lin CC, Bruinooge SS, Kirkwood MK, Hershman DL, Jemal A, Guadagnolo BA, et al. Association between geographic access to cancer care and receipt of radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2016;94(4):719–28.CrossRefPubMed Lin CC, Bruinooge SS, Kirkwood MK, Hershman DL, Jemal A, Guadagnolo BA, et al. Association between geographic access to cancer care and receipt of radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2016;94(4):719–28.CrossRefPubMed
23.
go back to reference Muralidhar V, Rose BS, Chen Y-W, Nezolosky MD, Nguyen PL. Association between travel distance and choice of treatment for prostate cancer: Does geography reduce patient choice? Int J Radiat Oncol Biol Phys. 2016;96(2):313–7.CrossRefPubMed Muralidhar V, Rose BS, Chen Y-W, Nezolosky MD, Nguyen PL. Association between travel distance and choice of treatment for prostate cancer: Does geography reduce patient choice? Int J Radiat Oncol Biol Phys. 2016;96(2):313–7.CrossRefPubMed
24.
go back to reference Prasad R, Zubizarreta E, Healy B, Hopkins K, Abdel-Wahab M. Radiotherapy in South Asia: Infrastructure, Human Resource Capacity, and Future Needs. Int J Radiat Oncol, Biol, Phys. 2017;99(2):E411–2.CrossRef Prasad R, Zubizarreta E, Healy B, Hopkins K, Abdel-Wahab M. Radiotherapy in South Asia: Infrastructure, Human Resource Capacity, and Future Needs. Int J Radiat Oncol, Biol, Phys. 2017;99(2):E411–2.CrossRef
25.
go back to reference Al Alwan NA. General oncology care in Iraq. Cancer in the Arab world. Singapore: Springer Singapore. 2022. p. 63–82. Al Alwan NA. General oncology care in Iraq. Cancer in the Arab world. Singapore: Springer Singapore. 2022. p. 63–82.
27.
go back to reference Kazemian A, Ghalehtaki R, Rezaei S, Soleymanian F, Mohammadi N, Aghili M, et al. The Incidence of Clinical Covid-19 Infection in Patients Undergoing Radiotherapy During the Two First Waves in a University Hospital in Iran. Basic & Clinical Cancer Research. 2022. Kazemian A, Ghalehtaki R, Rezaei S, Soleymanian F, Mohammadi N, Aghili M, et al. The Incidence of Clinical Covid-19 Infection in Patients Undergoing Radiotherapy During the Two First Waves in a University Hospital in Iran. Basic & Clinical Cancer Research. 2022.
28.
go back to reference The IAEA Directory of Radiotherapy Centres (DIRAC), https:/dirac.iaea.org/ (accessed on 02/2024) The IAEA Directory of Radiotherapy Centres (DIRAC), https:/dirac.iaea.org/ (accessed on 02/2024)
29.
go back to reference IAEA. Inequity in cancer care: A global perspective. Vienna: IAEA International Atomic Energy Agency; 2011. IAEA. Inequity in cancer care: A global perspective. Vienna: IAEA International Atomic Energy Agency; 2011.
30.
go back to reference Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer Interdisciplinary International Journal of the American Cancer Society. 2005;104(6):1129–37. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer Interdisciplinary International Journal of the American Cancer Society. 2005;104(6):1129–37.
31.
go back to reference Mackillop WJ, Kong W, Brundage M, Hanna TP, Zhang-Salomons J, McLaughlin P-Y, Tyldesley S. A comparison of evidence-based estimates and empirical benchmarks of the appropriate rate of use of radiation therapy in Ontario. Int J Radiat Oncol Biol Phys. 2015;91(5):1099–107.CrossRefPubMed Mackillop WJ, Kong W, Brundage M, Hanna TP, Zhang-Salomons J, McLaughlin P-Y, Tyldesley S. A comparison of evidence-based estimates and empirical benchmarks of the appropriate rate of use of radiation therapy in Ontario. Int J Radiat Oncol Biol Phys. 2015;91(5):1099–107.CrossRefPubMed
32.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
33.
go back to reference Dinmohamed AG, Visser O, Verhoeven RH, Louwman MW, Van Nederveen FH, Willems SM, et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol. 2020;21(6):750–1.CrossRefPubMedPubMedCentral Dinmohamed AG, Visser O, Verhoeven RH, Louwman MW, Van Nederveen FH, Willems SM, et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol. 2020;21(6):750–1.CrossRefPubMedPubMedCentral
Metadata
Title
PErspective and current status of Radiotherapy Service in IRan (PERSIR)-1 study: assessment of current external beam radiotherapy facilities, staff and techniques compared to the international guidelines
Authors
Arefeh Saeedian
Fatemeh-sadat Tabatabaei
Amirali Azimi
Mohammad Babaei
Marzieh Lashkari
Ebrahim Esmati
Zeinab Abiar
Leila Moadabshoar
Saleh Sandoughdaran
Mitchell Kamrava
Arya Amini
Reza Ghalehtaki
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12078-z

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine